27.4.2017 – Our new article on oral anticoagulation therapy among patients with atrial fibrillation has been published in Pharmacoepidemiology and Drug Safety.
Use of oral anticoagulation therapy remarkable decreases the risk of stroke and other thromboembolic events in patients with atrial fibrillation (AF). Despite of newer anticoagulants on the market, warfarin still is the most commonly used oral anticoagulant in many countries. Warfarin treatment is continuously monitored with laboratory tests (INR values). The percentage of time that the INR values are in the therapeutic range is called TTR. In clinical guidelines targeted TTR is at least 60–70%.
We studied 54 568 AF patients taking warfarin in a nationwide setting in Finland. In this register-based study linking data from several electronic medical records, TTR was calculated based on routinely measured INR values. We found that the higher the TTR, the better the patient outcome was; the risk of stroke, bleeding events, and mortality were all markedly decreased with an increasing time-dependent TTR. The results strongly emphasise that a new TTR target greater than 80% should be defined for optimal warfarin management in AF patients. These results are presented more in detail in our recent paper by Lehto et al. in Pharmacoepidemiology and Drug Safety.
Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Published in Pharmacoepidemiology and Drug Safety, doi: 10.1002/pds.4194. – Read abstract